Bio-Rad (BIO) Faces Low BioPharma Demand, Competitive Pressure
ZacksBio-Rad (BIO) is experiencing weaker sales in Asia as China is currently entangled in a challenging research funding environment, and Japan, too, is facing constrained funding issues.